Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

LH - Labcorp Holdings Inc. So'nggi Yangiliklar | Finranks

Home

/

LH

L

Labcorp Holdings Inc. (LH)

NYQ – Real vaqt narxi. Valyuta: USD

321.89

-0.53 (-0.16%)

Bozor ochiq: Aug 12, 2026, 3:11 PM EDT

322.42

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?

Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?

LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.

Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock

Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targeted treatment options for the deadliest form of skin cancer BURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.

Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation

Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation

LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.

Videolar

No Data

There is no data to display

Press-relizlar

Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targeted treatment options for the deadliest form of skin cancer BURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.

Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.